Since then, several biotech and pharmaceutical companies have put significant efforts into developing clinically suitable SMO inhibitors (SMOi), of which three compounds referred to as vismodegib, sonidegib and glasdegib have so far been approved for the treatment of locally advanced and metastatic BCC (vismodegib and sonidegib) [64,79,80,81,82] and in combination with low-dose chemotherapy for acute myeloid leukemia (AML; glasdegib) [83,84,85]. This evidence concerns the gene SMO and skin basal cell carcinoma.